Integrated platform combines advanced EEG technology and analytics to transform neurological research.
A Groundbreaking Collaboration
Neuroelectrics, known for high-definition brain stimulation and EEG technology, has teamed up with Neuronostics, a pioneer in digital biomarkers and EEG analysis. Together, they aim to deliver a seamless solution for clinical trials, benefiting pharmaceutical companies, CROs, and academic institutions.
Key features include:
- Advanced EEG hardware: Neuroelectrics provides cutting-edge devices.
- Proprietary BioEP analytics: Neuronostics enables precise data interpretation.
- Streamlined platform: Improves participant selection and trial efficiency.
“This collaboration makes trials more effective, offering significant benefits to people with neurological conditions,” said John Terry, Managing Director of Neuronostics.
Unlocking New Potential in Research
The partnership offers solutions to key challenges in neurological trials:
- Targeted cohort identification: A 20-minute EEG identifies participants with high seizure burdens.
- Actionable insights: Combines neurophysiologists’ expertise with cloud-based tools for precise analysis.
- Optimized protocols: Tailored designs ensure streamlined and reliable outcomes.
Pioneering the Future of Brain Health
“This integrated approach enables breakthroughs in neurology and psychiatry,” said Ana Maiques, CEO of Neuroelectrics.
The joint platform supports research in epilepsy, Alzheimer’s, and other neurological disorders, aiming to:
- Enhance trial precision.
- Accelerate treatment development.
- Improve efficiency for both sponsors and patients.
Follow MEDWIRE.AI for news on the latest healthcare partnerships and transformative innovations.
